PHARMACY

FDA approves new Sanofi-Aventis insulin pen

BY Alaric DeArment

BRIDGEWATER, N.J. The Food and Drug Administration has approved a new insulin pen from Sanofi-Aventis, the drug maker announced Thursday.

Apidra SoloSTAR (insulin glulisine [rDNA origin]) is a prefilled, disposable insulin pen containing the fast-acting insulin analog Apidra. Apidra is used to improve glycemic control in patients aged 4 and older with Type 1 and Type 2 diabetes. Its approval follows the 2007 approval and launch of Lantus SoloSTAR (insulin glargine [rDNA origin]).

 “People with diabetes have to contend with the challenges of carbohydrate counting, regular blood pressure monitoring and careful administration of their insulin,” Sanofi-Aventis U.S. VP metabolism marketing Angela Moskow stated. “Apidra SoloSTAR represents another innovation introduced by Sanofi-Aventis that offers patients a convenient option for administering their Apidra.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Take Care Health Systems opens New Orleans clinic

BY Antoinette Alexander

CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has opened a new clinic in the New Orleans area.

The new location makes four Take Care Clinics in that market. In total, the clinic operator has 332 clinics in 35 markets throughout 19 states. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Eli Lilly’s chemotherapy drug granted tentative approval by FDA

BY Alaric DeArment

ROCKVILLE, Md. The Food and Drug Administration has given tentative approval to a generic version of Eli Lilly & Co.’s chemotherapy drug Gemzar, agency records show.

The FDA issued the tentative approval Monday to Hospira’s 2 g gemcitabine hydrochloride injection. The drug is used to treat non-small cell lung cancer, pancreatic cancer, ovarian, breast cancer and others. 

Gemzar had worldwide sales of $1.6 billion in 2007, according to Lilly financial data. According to the FDA Orange Book, the drug will lose patent protection next year. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?